Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630564 · ClinicalTrials.gov registry record · Phase 1
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01630564: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01630564 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01630564, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of donor cord blood T-cells after stem cell transplant in treating patients with relapsed hematological malignancies. After umbilical cord blood transplant, stem cells are collected from the donor's cord blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by treatment. Removing the T cells and treating them in the laboratory before infusing them in the patient may also help boost the patient's immune system.
Interventions
- BIOLOGICAL Aldesleukin
- PROCEDURE Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
- BIOLOGICAL Umbilical Cord Blood-Derived Lymphocyte Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-03-11 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01630564
The ClinicalTrials.gov registry entry for NCT01630564 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aldesleukin is the first listed.
NCT01630564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01630564 about?
NCT01630564 is a clinical study titled "Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies". This phase I trial studies the side effects and best dose of donor cord blood T-cells after stem cell transplant in treating patients with relapsed hematological malignancies. After umbilical cord blood transplant, stem cells are collected from the donor's cord blood and stored. The stem cells are t...
What is the current status of trial NCT01630564?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-03-11. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT01630564?
The interventions under investigation include: Aldesleukin (BIOLOGICAL), Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion (PROCEDURE), Umbilical Cord Blood-Derived Lymphocyte Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01630564?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.